R1	Has_qualifier Arg1:T4 Arg2:T3	
R2	Has_temporal Arg1:T4 Arg2:T1	
R3	AND Arg1:T6 Arg2:T7	
R4	Has_temporal Arg1:T6 Arg2:T9	
R5	Has_index Arg1:T16 Arg2:T17	
R6	Has_temporal Arg1:T15 Arg2:T16	
T1	Temporal 11 20	currently
T3	Qualifier 35 53	Novartis-sponsored
T4	Observation 21 34;55 108	enrolled in a Oncology Clinical Development & Medical Affairs study
T2	Drug 119 128	nilotinib
T5	Non-representable 133 189	has fulfilled all their requirements in the parent study
T6	Procedure 232 241	treatment
T7	Drug 247 256	nilotinib
T8	Non-representable 258 291	as determined by the investigator
T9	Temporal 202 211	currently
T10	Observation 318 328;363 406	compliance with the parent study protocol requirements
T11	Non-representable 330 361	as assessed by the investigator
T12	Mood 408 419;432 463	Willingness to comply with scheduled visits
T13	Mood 424 463	ability to comply with scheduled visits
T14	Mood 408 419;432 446;465 480	Willingness to comply with treatment plans
T15	Observation 513 537	Written informed consent
T16	Temporal 547 584	prior to enrolling in roll-over study
T17	Reference_point 556 584	enrolling in roll-over study
